The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies

Catia Traversari, Sarah Marktel, Zulma Magnani, Patrizia Mangia, Vincenzo Russo, Fabio Ciceri, Chiara Bonini, Claudio Bordignon

Research output: Contribution to journalArticle

Abstract

Gene therapy is a promising therapeutic strategy for genetic and acquired hematologic diseases. With the improvements in gene transfer and expression, factors affecting safety and efficacy of gene therapy can now be evaluated to establish the best clinical benefit-to-risk ratio. The induction of immune responses against gene therapy components is one of the potential limitations. We studied the occurrence of such event in 23 patients treated with donor lymphocyte infusions (DLIs), with lymphocytes transduced to express the HSV-TK suicide gene for relapse of hematologic malignancies occurring after allogeneic hematopoietic stem cell transplantation (HSCT). The suicide gene was used to selectively control graftversus-host disease (GvHD). Seven patients given infusions late after HSCT developed an immune response against the transgene. Immunization involved appearance of thymidine kinase (TK)-specific CD8 + effectors and required a level of immunocompetence at the time of TKDLI that can be achieved only several months after transplantation. This did not prevent graft-versus-leukemia (GvL) effect of the TK-DLI, since 5 of 7 immunized patients maintained the complete remission achieved prior to immunization. We suggest that appropriate study designs taking into account the immune suppression of the patient and time-kinetics of GvL mediated by TK-transduced donor lymphocytes may allow the full exploitation of TKDLI.

Original languageEnglish
Pages (from-to)4708-4715
Number of pages8
JournalBlood
Volume109
Issue number11
DOIs
Publication statusPublished - Jun 1 2007

Fingerprint

Lymphocytes
Thymidine Kinase
Hematopoietic Stem Cell Transplantation
Hematologic Neoplasms
Stem cells
Gene therapy
Suicide
Genes
Tissue Donors
Genetic Therapy
Immunization
Grafts
Leukemia
Transplantation (surgical)
Gene Components
Gene transfer
Transplants
Transfer Factor
Immunocompetence
Hematologic Diseases

ASJC Scopus subject areas

  • Hematology

Cite this

The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. / Traversari, Catia; Marktel, Sarah; Magnani, Zulma; Mangia, Patrizia; Russo, Vincenzo; Ciceri, Fabio; Bonini, Chiara; Bordignon, Claudio.

In: Blood, Vol. 109, No. 11, 01.06.2007, p. 4708-4715.

Research output: Contribution to journalArticle

@article{bed94053dd824d448517774d02a90f03,
title = "The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies",
abstract = "Gene therapy is a promising therapeutic strategy for genetic and acquired hematologic diseases. With the improvements in gene transfer and expression, factors affecting safety and efficacy of gene therapy can now be evaluated to establish the best clinical benefit-to-risk ratio. The induction of immune responses against gene therapy components is one of the potential limitations. We studied the occurrence of such event in 23 patients treated with donor lymphocyte infusions (DLIs), with lymphocytes transduced to express the HSV-TK suicide gene for relapse of hematologic malignancies occurring after allogeneic hematopoietic stem cell transplantation (HSCT). The suicide gene was used to selectively control graftversus-host disease (GvHD). Seven patients given infusions late after HSCT developed an immune response against the transgene. Immunization involved appearance of thymidine kinase (TK)-specific CD8 + effectors and required a level of immunocompetence at the time of TKDLI that can be achieved only several months after transplantation. This did not prevent graft-versus-leukemia (GvL) effect of the TK-DLI, since 5 of 7 immunized patients maintained the complete remission achieved prior to immunization. We suggest that appropriate study designs taking into account the immune suppression of the patient and time-kinetics of GvL mediated by TK-transduced donor lymphocytes may allow the full exploitation of TKDLI.",
author = "Catia Traversari and Sarah Marktel and Zulma Magnani and Patrizia Mangia and Vincenzo Russo and Fabio Ciceri and Chiara Bonini and Claudio Bordignon",
year = "2007",
month = "6",
day = "1",
doi = "10.1182/blood-2006-04-015230",
language = "English",
volume = "109",
pages = "4708--4715",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies

AU - Traversari, Catia

AU - Marktel, Sarah

AU - Magnani, Zulma

AU - Mangia, Patrizia

AU - Russo, Vincenzo

AU - Ciceri, Fabio

AU - Bonini, Chiara

AU - Bordignon, Claudio

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Gene therapy is a promising therapeutic strategy for genetic and acquired hematologic diseases. With the improvements in gene transfer and expression, factors affecting safety and efficacy of gene therapy can now be evaluated to establish the best clinical benefit-to-risk ratio. The induction of immune responses against gene therapy components is one of the potential limitations. We studied the occurrence of such event in 23 patients treated with donor lymphocyte infusions (DLIs), with lymphocytes transduced to express the HSV-TK suicide gene for relapse of hematologic malignancies occurring after allogeneic hematopoietic stem cell transplantation (HSCT). The suicide gene was used to selectively control graftversus-host disease (GvHD). Seven patients given infusions late after HSCT developed an immune response against the transgene. Immunization involved appearance of thymidine kinase (TK)-specific CD8 + effectors and required a level of immunocompetence at the time of TKDLI that can be achieved only several months after transplantation. This did not prevent graft-versus-leukemia (GvL) effect of the TK-DLI, since 5 of 7 immunized patients maintained the complete remission achieved prior to immunization. We suggest that appropriate study designs taking into account the immune suppression of the patient and time-kinetics of GvL mediated by TK-transduced donor lymphocytes may allow the full exploitation of TKDLI.

AB - Gene therapy is a promising therapeutic strategy for genetic and acquired hematologic diseases. With the improvements in gene transfer and expression, factors affecting safety and efficacy of gene therapy can now be evaluated to establish the best clinical benefit-to-risk ratio. The induction of immune responses against gene therapy components is one of the potential limitations. We studied the occurrence of such event in 23 patients treated with donor lymphocyte infusions (DLIs), with lymphocytes transduced to express the HSV-TK suicide gene for relapse of hematologic malignancies occurring after allogeneic hematopoietic stem cell transplantation (HSCT). The suicide gene was used to selectively control graftversus-host disease (GvHD). Seven patients given infusions late after HSCT developed an immune response against the transgene. Immunization involved appearance of thymidine kinase (TK)-specific CD8 + effectors and required a level of immunocompetence at the time of TKDLI that can be achieved only several months after transplantation. This did not prevent graft-versus-leukemia (GvL) effect of the TK-DLI, since 5 of 7 immunized patients maintained the complete remission achieved prior to immunization. We suggest that appropriate study designs taking into account the immune suppression of the patient and time-kinetics of GvL mediated by TK-transduced donor lymphocytes may allow the full exploitation of TKDLI.

UR - http://www.scopus.com/inward/record.url?scp=34249748406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249748406&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-04-015230

DO - 10.1182/blood-2006-04-015230

M3 - Article

C2 - 17327417

AN - SCOPUS:34249748406

VL - 109

SP - 4708

EP - 4715

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -